SymBio's bendamustine moves forward in first-line setting in Japan
This article was originally published in Scrip
Executive Summary
SymBio Pharmaceuticals is eyeing expanded use of its first commercialised product, the anticancer bendamustine, with the start of a Phase II development programme in Japan for the first-line treatment of low-grade non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma.